Doxercalciferol

Doxercalciferol is a synthetic vitamin D analog that plays a crucial role in the regulation of calcium and phosphorus metabolism. It is primarily used in the treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD). Doxercalciferol acts by inhibiting the secretion of parathyroid hormone (PTH) by the parathyroid gland, which is often elevated in patients with CKD.
Mechanism of Action[edit]
Doxercalciferol is activated in the liver to form its active metabolite, 1α,25-dihydroxyvitamin D2. This active form binds to the vitamin D receptor (VDR) in the parathyroid gland, leading to a decrease in PTH secretion. The reduction in PTH levels helps to normalize serum calcium and phosphorus levels, thereby mitigating the risk of bone disease associated with secondary hyperparathyroidism.
Indications[edit]
Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients undergoing chronic renal dialysis. It is also used in patients with CKD not yet on dialysis to reduce elevated levels of PTH.
Pharmacokinetics[edit]
After administration, doxercalciferol is rapidly absorbed and undergoes activation in the liver. Its pharmacokinetics may vary among individuals, particularly in patients with liver impairment, which can affect the drug's activation.
Side Effects[edit]
The use of doxercalciferol can lead to several side effects, including hypercalcemia (high calcium levels in the blood), hyperphosphatemia (high phosphate levels in the blood), and hypercalciuria (high calcium levels in the urine). Monitoring of serum calcium and phosphorus levels is recommended during treatment.
Administration and Dosage[edit]
Doxercalciferol is available in both oral and intravenous formulations. The dosage is individualized based on the patient's baseline PTH levels, and adjustments are made based on the response and any adverse effects experienced by the patient.
Conclusion[edit]
Doxercalciferol represents an important option in the management of secondary hyperparathyroidism in patients with CKD. Its ability to effectively reduce PTH levels, while managing calcium and phosphorus balance, makes it a valuable tool in preventing the bone disease associated with this condition.
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian